|
Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987
RTT News (RTTNews) – Targacept Inc. (TRGT: News ) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the US, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … |
View full post on asthma – Google News